How to Appeal a UnitedHealthcare Dupixent (dupilumab) - Prior Authorization/Medical Necessity Denial
UnitedHealthcare decides coverage for Dupixent (dupilumab) - Prior Authorization/Medical Necessity under policy 2025 P 2116-22. The most effective appeal shows, point by point, that you meet UnitedHealthcare's own criteria below.
What UnitedHealthcare requires for coverage
UnitedHealthcare considers Dupixent (dupilumab) - Prior Authorization/Medical Necessity medically necessary when the following criteria (from 2025 P 2116-22) are met:
- ATOPIC DERMATITIS: Diagnosis of moderate-to-severe chronic atopic dermatitis AND failure/contraindication/intolerance to 2 of: (a) medium/high/very-high potency topical corticosteroid, (b) topical calcineurin inhibitor, (c) Eucrisa AND not combined with biologic immunomodulator or JAK inhibitor for same indication AND prescribed by dermatologist/allergist/immunologist. Auth 12 months.
- ASTHMA: Moderate-to-severe asthma, uncontrolled (ACQ>1.5 or ACT<20 or 2+ steroid bursts/yr or ER visit or FEV1<80%) AND eosinophilic phenotype (eos>=150 cells/uL) OR oral corticosteroid dependent AND used with maximally dosed ICS/LABA combo AND not combined with anti-IL5/anti-IgE/TSLP inhibitor AND prescribed by allergist/immunologist/pulmonologist. Auth 12 months.
- CRSwNP: Chronic rhinosinusitis with nasal polyposis (2+ symptoms >12 weeks + endoscopy/CT findings + bilateral polyps or prior surgical removal) AND prior sinus surgery or systemic corticosteroids in past 2 years or failed 2 of: nasal saline/intranasal corticosteroids/antileukotrienes AND add-on to intranasal corticosteroids AND prescribed by allergist/immunologist/otolaryngologist/pulmonologist. Auth 12 months.
- EOSINOPHILIC ESOPHAGITIS: Diagnosis of EoE AND symptoms of esophageal dysfunction AND peak >=15 intraepithelial eosinophils per HPF on biopsy AND secondary causes ruled out AND failed 8-week trial of PPI or topical esophageal corticosteroid AND prescribed by gastroenterologist/allergist. Auth 12 months.
- PRURIGO NODULARIS: Diagnosis of PN AND >=20 nodular lesions AND failed prior treatment (topical corticosteroids/calcineurin inhibitors/capsaicin) AND prescribed by dermatologist/allergist/immunologist. Auth 12 months.
- COPD: Diagnosis of COPD AND post-BD FEV1/FVC <0.7 AND post-BD FEV1 30-70% predicted AND eosinophils >=300 cells/uL AND 2+ exacerbations/yr on triple therapy (LAMA/LABA/ICS) or dual+ICS failure AND chronic productive cough >=3 months AND prescribed by allergist/immunologist/pulmonologist. Auth 12 months.
- CHRONIC SPONTANEOUS URTICARIA: Diagnosis of CSU AND symptomatic despite 2-week trial of 2 H1-antihistamines OR combination therapy with antihistamine+another agent AND not combined with Xolair AND prescribed by allergist/dermatologist/immunologist. Auth 12 months.
- BULLOUS PEMPHIGOID: Diagnosis of bullous pemphigoid AND prescribed by dermatologist/allergist/immunologist. Auth 12 months.
How to appeal this denial
Frame your appeal around the specific criterion you satisfy. Quote the 2025 P 2116-22 language above, then show — with your physician's records and clinical evidence — exactly how your situation meets it. Demand that UnitedHealthcare either approve the claim or identify the precise criterion they believe you fail. CareCost Appeals assembles this automatically: it cites the policy, pulls verified clinical evidence, and applies your state and federal appeal rights.
Source: UnitedHealthcare medical policy 2025 P 2116-22 — view the published policy.